Is the imported drug Roprostim/Romigrastim for injection included in the medical insurance?

The medical insurance situation of the imported drug Romiplostim/Romiplostim for injection (Romiplostim) in China has attracted widespread attention. Roprostim is a recombinant human thrombopoietin, mainly used to treat idiopathic thrombocytopenic purpura (ITP). Although the original drug has been launched in China and is included in medical insurance, patients still face certain difficulties when actually purchasing it because it has not been on the market for a long time.

The inclusion of Roprostim in the medical insurance catalog means that part of its cost can be reimbursed by medical insurance, which is undoubtedly good news for patients who need to use this drug for a long time. However, due to the short time the drug has been on the market, market supply and patient access channels are not yet fully mature, causing some patients to encounter obstacles in actual purchase. For example, some hospitals may not be able to provide the drug due to insufficient inventory or complicated procurement processes. Patients need to consult multiple medical institutions, which increases the inconvenience of treatment.

In addition, although Roprostim is included in the medical insurance catalog, the specific reimbursement ratio and conditions may vary from region to region. Some places have relatively loose medical insurance policies, while some areas may have reimbursement restrictions, which makes the financial burden on patients vary in different areas. Therefore, before using Roprostim, patients must understand the local medical insurance policy to ensure smooth reimbursement.

As the country pays more attention to patients with chronic diseases and rare diseases, relevant policies are constantly adjusted. Experts pointed out that if more clinical data and economic benefits evaluation of loplastin can be provided, this will further promote its status in medical insurance. In the future, it is expected that through policy promotion, patient accessibility will be improved so that more people can benefit from this effective treatment option.